1. Quick Facts
Category: Erythropoietin-Derived Tissue Protective Peptide
Risk Level: Moderate
Research Status: Emerging Research
Administration: Subcutaneous or Intramuscular Injection
Typical Frequency: Once or Twice Daily
Estimated Half-Life: Approximately 2–5 Minutes
Primary Research Interest: Nerve Repair / Inflammation Reduction / Tissue Protection
This material is provided strictly for educational and informational purposes related to peptide research and tissue-protective compounds. ARA-290 is a biologically active experimental peptide that may influence inflammatory and neurological signaling pathways. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
2. Summary
ARA-290 is an experimental peptide derived from erythropoietin (EPO) signaling pathways, specifically engineered to target tissue-protective and anti-inflammatory mechanisms without substantially stimulating red blood cell production.
Research interest in ARA-290 primarily centers around neuropathy, nerve repair, inflammation modulation, chronic pain support, and tissue protection. Unlike traditional EPO-based therapies, ARA-290 was designed to emphasize regenerative signaling while minimizing erythropoietic activity.
What People Commonly Claim
- Powerful nerve regeneration effects
- Relief from chronic neuropathic pain
- Accelerated recovery from nerve injuries
- Systemic anti-inflammatory benefits
- The regenerative benefits of erythropoietin without the blood-thickening risks
What the Literature Actually Shows
- ARA-290 was engineered to activate tissue-protective repair pathways associated with erythropoietin while minimizing stimulation of red blood cell production.
- Human studies have investigated ARA-290 in conditions including small fiber neuropathy, sarcoidosis-associated neuropathy, and type 2 diabetes.
- Several clinical studies have reported improvements in neuropathic symptoms, quality-of-life measures, and objective markers of nerve fiber health.
- The compound remains investigational, and larger confirmatory trials are needed to establish long-term efficacy and optimal treatment protocols.
- Although early findings are encouraging, ARA-290 has not received broad regulatory approval for routine clinical use.
3. Reconstitution Guide
- Vial Size: 10 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 2 mL
- Final Concentration: 5.00 mg/mL
At this concentration:
• 2 mg = 0.400 mL (40 units)
• 4 mg = 0.800 mL (80 units)
*Different vial sizes may limit reconstitution volume. If your product differs from the specifications listed here, please use the Peptide Calculator to calculate custom concentrations and dosing protocols.
4. Route of Administration
ARA-290 is most commonly administered as a subcutaneous injectable peptide, though intramuscular administration is also discussed in some research and anecdotal contexts.
- Primary Route: SubQ Injection
- Alternative Route: Intramuscular Injection
- Administration Notes: Due to the extremely short half-life, consistent administration timing is considered important for maximal effect.
5. Common Research Protocols
- Product Strength: 5.00 mg/mL
- Typical Delivered Amount: 2–4 mg daily, not to exceed 8 mg per day
- Frequency: Once or twice daily due to the short half-life
- Cycle Length: 8 weeks on / 4 weeks off
- Special Notes: ARA-290 was specifically engineered to preserve the tissue-protective and anti-inflammatory properties of erythropoietin while minimizing effects on red blood cell production. Because of its extremely short half-life, consistent administration timing is commonly emphasized in research protocols. Human studies have investigated ARA-290 for neuropathy, chronic pain, and tissue repair applications, with many researchers viewing it as one of the more promising regenerative peptides currently under investigation.
6. Mechanism of Action
ARA-290 selectively activates innate repair receptor (IRR) pathways associated with tissue protection and inflammatory modulation.
Unlike full erythropoietin signaling, ARA-290 was designed to minimize erythropoietic activity while preserving regenerative and anti-inflammatory properties.
Potential downstream effects discussed in research include:
- Reduced inflammatory signaling
- Potential nerve repair support
- Reduced neuropathic pain signaling
- Improved tissue recovery mechanisms
- Protection against inflammatory tissue damage
7. Potential Benefits
- Potential neuropathy symptom reduction
- Reduced inflammatory signaling
- Possible chronic pain support
- Potential nerve regeneration support
- Improved tissue recovery mechanisms
- Non-erythropoietic tissue protective signaling
8. Potential Risks / Side Effects
Moderate
- Injection site irritation
- Headaches
- Fatigue
- Nausea
- Dizziness
- Limited long-term human safety data
- Potential immune signaling alterations
9. Half-Life
ARA-290 has an extremely short estimated half-life commonly referenced in the range of approximately 2–5 minutes.
Because of this short duration, administration timing and consistency are frequently emphasized in experimental protocols.
10. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
11. Contraindications / Warnings
- Pregnancy or breastfeeding
- Active autoimmune disorders
- Uncontrolled inflammatory disease
- Known hypersensitivity to peptide compounds
12. Further Study
ARA-290 possesses a larger body of human research than many experimental peptides. Readers interested in a deeper understanding of the compound’s mechanisms, clinical evidence, and therapeutic potential may find the following resources helpful.
Tier 1 — Essential Reading
Targeting the Innate Repair Receptor to Treat Neuropathy
Probably the best overall introduction to ARA-290 (Cibinetide), including its mechanism of action, human clinical data, and future therapeutic potential.
Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy
A foundational randomized, double-blind human study demonstrating improvements in neuropathic symptoms while maintaining a favorable safety profile.
ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes
Human clinical evidence exploring both neuropathic symptom improvement and metabolic outcomes.
Tier 2 — Advanced Mechanism Reading
Discovery of a Master Regulator of Injury and Healing
Explains the origin of the Innate Repair Receptor concept and the biological rationale behind ARA-290.
Long-lasting Effects of a Non-Erythropoietic Small Peptide Derived from Erythropoietin
Abstract/Reference Only. Addresses the apparent paradox of a very short plasma half-life producing biological effects that may persist for days or weeks.
An Engineered Non-Erythropoietic Erythropoietin-Derived Peptide: From Mechanism to Therapeutic Potential
Abstract/Reference Only. A broader review of anti-inflammatory, anti-apoptotic, and regenerative applications beyond neuropathy.
Tier 3 — Emerging and Specialized Research
Cibinetide Improves Corneal Nerve Fiber Abundance in Sarcoidosis
One of the most interesting human studies, reporting objective improvements in corneal nerve fiber density rather than symptom improvement alone.
CKF Note: While ARA-290 remains an investigational compound, it possesses a larger and more diverse body of human clinical evidence than many experimental peptides. Readers are encouraged to review both the promising findings and the remaining evidence gaps before drawing conclusions regarding efficacy.
13. Research References
- PubMed
- PubMed Central (PMC)
- NIH Publications
- Neuropathy and tissue repair literature
- Peer-reviewed inflammatory signaling journals
14. Last Reviewed
June 2026